Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy.

Microsoft Corporation earnings face AI return scrutiny. See key Q1 tests for Azure growth, margins, and cash flow resilience.

In the current environment, Bloom Energy would have required an entirely flawless beat-and-raise quarter to support its still ...

IDEX Corporation (IEX) continues to deliver robust revenue and profit growth across key segments, particularly Health & ...

IVES offers concentrated exposure to leading AI and tech names, with a compelling PEG ratio of 0.77x and a corrected P/E ...

Analyze VYMI: a low-cost international dividend ETF with 3.84% yield, strong dividend growth, solid value, and buy-rated ...

Wider credit spreads make high-yield bonds worthwhile investment opportunities. SPHY is a simple high-yield corporate bond ...

First Trust Dow Jones Internet Index Fund ETF review: why its growth and quality strengths may not outweigh weak performance.

The following slide deck was published by Metropolitan Bank Holding Corp. in conjunction with their 2026 Q3 earnings call.

Coeur's reported silver cost at Palmarejo is $27.69/oz. Credit the gold from the same rock and it falls to about $6. Find out ...

Palantir’s AI-driven revenue growth, margin strength, and backlog signal strong momentum ahead of Q3 earnings. Read why PLTR ...

Realty Income’s size forces reinvention as it expands into new sectors, bringing both opportunities and risks. Click to read ...